203 related articles for article (PubMed ID: 2035258)
1. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.
Kovacs K; Stefaneanu L; Horvath E; Lloyd RV; Lancranjan I; Buchfelder M; Fahlbusch R
Virchows Arch A Pathol Anat Histopathol; 1991; 418(5):439-46. PubMed ID: 2035258
[TBL] [Abstract][Full Text] [Related]
2. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report.
Kovacs K; Stefaneanu L; Horvath E; Buchfelder M; Fahlbusch R; Becker W
J Neurosurg; 1995 May; 82(5):886-90. PubMed ID: 7714616
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of SNAP-25 protein in adenomas of the human pituitary.
Rotondo F; Kovacs K; Scheithauer BW; Horvath E; Bell CD; Lloyd RV; Cusimano M
Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):477-81. PubMed ID: 18633321
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous sparsely-granulated prolactin-producing pituitary adenomas in aging rats. A prospective study of the effect of bromocriptine.
McComb DJ; Hellmann P; Kovacs K; Scott D; Evans WS; Burdman JA; Thorner MO
Neuroendocrinology; 1985 Sep; 41(3):201-11. PubMed ID: 4047338
[TBL] [Abstract][Full Text] [Related]
5. Clinical and morphological findings in two cases of bromocriptine-treated prolactinomas.
Anniko M; Wersäll J
Acta Pathol Microbiol Scand A; 1981 Jan; 89(1):41-7. PubMed ID: 7223426
[TBL] [Abstract][Full Text] [Related]
6. Prolactin receptor messenger ribonucleic acid in normal and neoplastic human pituitary tissues.
Jin L; Qian X; Kulig E; Scheithauer BW; Calle-Rodrigue R; Abboud C; Davis DH; Kovacs K; Lloyd RV
J Clin Endocrinol Metab; 1997 Mar; 82(3):963-8. PubMed ID: 9062514
[TBL] [Abstract][Full Text] [Related]
7. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors.
Maxson WS; Dudzinski M; Handwerger SH; Hammond CB
Fertil Steril; 1984 Feb; 41(2):218-23. PubMed ID: 6698215
[TBL] [Abstract][Full Text] [Related]
8. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine.
Lei T; Bai X; Liu K; Hu W; Xue D; Jiang X
J Tongji Med Univ; 1998; 18(3):161-3. PubMed ID: 10806816
[TBL] [Abstract][Full Text] [Related]
9. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
10. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas.
Lamberts SW; Verleun T; Oosterom R
Neuroendocrinology; 1982; 34(5):339-42. PubMed ID: 7078703
[TBL] [Abstract][Full Text] [Related]
11. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
Bevan JS; Burke CW
Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas.
Landolt AM; Minder H; Osterwalder V; Landolt TA
Experientia; 1983 Jun; 39(6):625-6. PubMed ID: 6852202
[TBL] [Abstract][Full Text] [Related]
13. Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
Jones TH; Figueroa CD; Smith CM; Cullen DR; Bhoola KD
J Endocrinol; 1992 Jul; 134(1):149-54. PubMed ID: 1500840
[TBL] [Abstract][Full Text] [Related]
14. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study.
Bergström M; Muhr C; Lundberg PO; Bergström K; Gee AD; Fasth KJ; Långström B
J Comput Assist Tomogr; 1987; 11(5):815-9. PubMed ID: 3498743
[TBL] [Abstract][Full Text] [Related]
15. Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis.
Mori H; Mori S; Saitoh Y; Arita N; Aono T; Uozumi T; Mogami H; Matsumoto K
Cancer; 1985 Jul; 56(2):230-8. PubMed ID: 4005795
[TBL] [Abstract][Full Text] [Related]
16. Macroprolactinomas and functionless pituitary tumours. Immunostaining and effect of dopamine agonist therapy.
Gasser RW; Mueller-Holzner E; Skrabal F; Finkenstedt G; Mayr U; Tabarelli M; Spoendlin H; Grunert V; Twerdy K
Acta Endocrinol (Copenh); 1987 Oct; 116(2):253-9. PubMed ID: 3116800
[TBL] [Abstract][Full Text] [Related]
17. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.
Kontogeorgos G; Horvath E; Kovacs K; Coire C; Lloyd RV; Scheithauer BW; Smyth HS
Acta Neuropathol; 2006 Jan; 111(1):46-52. PubMed ID: 16328513
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of specific dopamine receptors on human pituitary adenomas.
Koga M; Nakao H; Arao M; Sato B; Noma K; Morimoto Y; Kishimoto S; Mori S; Uozumi T
Acta Endocrinol (Copenh); 1987 Apr; 114(4):595-602. PubMed ID: 3577589
[TBL] [Abstract][Full Text] [Related]
19. Transformation of a human mixed GH-PRL adenoma cell population in response to long-term bromocriptine treatment.
Bácsy E; Fazekas I; Slowik F; Pásztor E; Czirják S
Folia Histochem Cytobiol; 1997; 35(2):69-74. PubMed ID: 9151080
[TBL] [Abstract][Full Text] [Related]
20. Pathology of prolactin cell adenomas of the human pituitary.
Horvath E; Kovacs K
Semin Diagn Pathol; 1986 Feb; 3(1):4-17. PubMed ID: 3303229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
